BTCY
Biotricity, Inc.
Price Chart
Latest Quote
$0.12
+0.00 (+1.14%)
Current Price
| Previous Close | $0.11 |
| Open | $0.12 |
| Day High | $0.12 |
| Day Low | $0.12 |
| Volume | 10 |
Stock Information
| Shares Outstanding | 28.44M |
| Total Debt | $27.09M |
| Cash Equivalents | $1.43M |
| Revenue | $15.45M |
| Net Income | $-4.70M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $3.31M |
| EPS (TTM) | $-0.16 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $32.50M |
| Sales | $15.45M |
| Income | $-4.70M |
| Book/sh | $-1.22 |
| Cash/sh | $0.05 |
| Employees | 46 |
Financial Ratios
| Quick Ratio | 0.13 |
| Current Ratio | 0.21 |
Returns & Margins
| ROA | 1.51% |
| Gross Margin | 81.09% |
| Operating Margin | 11.06% |
| Profit Margin | -25.99% |
Ownership
| Insider Ownership | 36.76% |
| Institutional Ownership | 2.11% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.27 |
| P/S | 0.21 |
| P/B | -0.09 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.16 |
| SMA50 | $0.21 |
| SMA200 | $0.38 |
| RSI | 32.88 |
| ATR | 0.0253 |
| Shares Float | 16.56M |
| Short Float | 2.25% |
| Short Ratio | 5.50 |
| Volatility | 1.15 |
| Rel Volume | 0.00 |
Performance History
| Week | -11.60% |
| Month | -52.15% |
| Quarter | -49.65% |
| 6 Months | -75.64% |
| YTD | -61.40% |
| Year | -77.43% |
| 3 Years | -97.20% |
| 5 Years | -99.30% |
| 10 Years | -98.98% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $0.12 | 10 |
| 2026-06-04 | $0.13 | 0 |
| 2026-06-03 | $0.13 | 11,474 |
| 2026-06-02 | $0.14 | 2,911 |
| 2026-06-01 | $0.11 | 93,072 |
| 2026-05-29 | $0.13 | 4,166 |
| 2026-05-28 | $0.13 | 21,512 |
| 2026-05-27 | $0.13 | 96,582 |
| 2026-05-26 | $0.14 | 191,299 |
| 2026-05-22 | $0.12 | 83,456 |
| 2026-05-21 | $0.11 | 283,329 |
| 2026-05-20 | $0.10 | 732,966 |
| 2026-05-19 | $0.16 | 482,520 |
| 2026-05-18 | $0.17 | 384,197 |
| 2026-05-15 | $0.19 | 430,942 |
| 2026-05-14 | $0.20 | 207,109 |
| 2026-05-13 | $0.25 | 40,534 |
| 2026-05-12 | $0.24 | 17,590 |
| 2026-05-11 | $0.24 | 1,121 |
| 2026-05-08 | $0.25 | 3,523 |
| 2026-05-07 | $0.26 | 40,748 |
| 2026-05-06 | $0.24 | 3,219 |
| 2026-05-05 | $0.26 | 11,209 |
About Biotricity, Inc.
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux and Biocore Pro, an integrated ECG device and software that utilizes wet electrodes for cardiac outpatient monitoring (COM) market; Biocore, a Holter and Extended Holter monitors for cardiac diagnostics; Biocare which support medical practitioners to gather data, and regularly monitor and treat patients with two or more chronic care conditions; Bioheart that offers preventative care and disease management solutions; and Biokit, a remote patient monitoring kit for cardiac patients that had other chronic conditions such as hypertension or COPD. Biotricity, Inc. is based in Redwood City, California.
đ° Latest News
Biotricity Inc (BTCY) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic AI ...
GuruFocus.com âĸ 2026-02-12T05:02:00ZThe Zacks Analyst Blog Highlights Hims & Hers Health, Biotricity and Privia Health
Zacks âĸ 2025-12-24T14:58:00Z
3 Healthcare IT Stocks Up More Than 20% in 2025 With More Room to Run
Zacks âĸ 2025-12-23T19:08:00Z
Biotricity Inc (BTCY) Q2 2026 Earnings Call Highlights: Revenue Surge and Strategic Expansion
GuruFocus.com âĸ 2025-11-15T05:00:35Z
Biotricity Inc. (BTCY) Reports Q2 Loss, Lags Revenue Estimates
Zacks âĸ 2025-11-14T22:00:02Z
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates
Zacks âĸ 2025-11-13T14:40:02Z
Pulmonx Corporation (LUNG) Reports Q3 Loss, Beats Revenue Estimates
Zacks âĸ 2025-11-12T22:30:03Z
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
Zacks âĸ 2025-11-07T13:20:03Z
Doximity (DOCS) Tops Q2 Earnings and Revenue Estimates
Zacks âĸ 2025-11-06T22:25:02Z
iRhythm Technologies (IRTC) Reports Q3 Loss, Beats Revenue Estimates
Zacks âĸ 2025-10-30T21:45:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $3,225,803 | $3,707,064 | $4,197,024 | $3,080,116 |
| Cost Of Revenue | $3,225,803 | $3,707,064 | $4,197,024 | $3,080,116 |
| Total Revenue | $13,790,294 | $12,063,345 | $9,639,057 | $7,650,269 |
| Operating Revenue | $13,790,294 | $12,063,345 | $9,639,057 | $7,650,269 |
| Expenses | ||||
| Interest Expense | $5,201,854 | $5,191,723 | $2,582,618 | $10,569,593 |
| Total Expenses | $16,239,260 | $20,891,614 | $25,048,768 | $24,387,072 |
| Other Income Expense | $-770,359 | $-74,291 | $-665,814 | $-1,824,081 |
| Other Non Operating Income Expenses | $-216,503 | $-84,068 | $-181,941 | $-1,140,522 |
| Net Non Operating Interest Income Expense | $-5,201,854 | $-5,191,723 | $-2,582,618 | $-10,569,593 |
| Interest Expense Non Operating | $5,201,854 | $5,191,723 | $2,582,618 | $10,569,593 |
| Operating Expense | $13,013,457 | $17,184,550 | $20,851,744 | $21,306,956 |
| General And Administrative Expense | $10,857,797 | $14,612,724 | $17,621,865 | $18,562,369 |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,421,179 | $-14,094,283 | $-18,658,143 | $-29,130,477 |
| Net Interest Income | $-5,201,854 | $-5,191,723 | $-2,582,618 | $-10,569,593 |
| Normalized Income | $-7,867,323 | $-14,104,060 | $-18,174,270 | $-28,446,918 |
| Net Income From Continuing And Discontinued Operation | $-8,421,179 | $-14,094,283 | $-18,658,143 | $-29,130,477 |
| Total Operating Income As Reported | $-2,448,966 | $-8,828,269 | $-15,409,711 | - |
| Net Income Common Stockholders | $-11,942,000 | $-14,928,960 | $-19,533,683 | $-30,219,454 |
| Net Income | $-8,421,179 | $-14,094,283 | $-18,658,143 | $-29,130,477 |
| Net Income Including Noncontrolling Interests | $-8,421,179 | $-14,094,283 | $-18,658,143 | $-29,130,477 |
| Net Income Continuous Operations | $-8,421,179 | $-14,094,283 | $-18,658,143 | $-29,130,477 |
| Pretax Income | $-8,421,179 | $-14,094,283 | $-18,658,143 | $-29,130,477 |
| Operating Income | $-2,448,966 | $-8,828,269 | $-15,409,711 | $-16,736,803 |
| Gross Profit | $10,564,491 | $8,356,281 | $5,442,033 | $4,570,153 |
| Per Share | ||||
| Diluted EPS | $-0.56 | $-1.66 | $-2.26 | $-3.99 |
| Basic EPS | $-0.56 | $-1.66 | $-2.26 | $-3.99 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,659,516 | $-8,906,384 | $-15,585,699 | $-17,875,017 |
| Total Unusual Items | $-553,856 | $9,777 | $-483,873 | $-683,559 |
| Total Unusual Items Excluding Goodwill | $-553,856 | $9,777 | $-483,873 | $-683,559 |
| Reconciled Depreciation | $5,953 | $5,953 | $5,953 | $2,308 |
| EBITDA (Bullshit earnings) | $-3,213,372 | $-8,896,607 | $-16,069,572 | $-18,558,576 |
| EBIT | $-3,219,325 | $-8,902,560 | $-16,075,525 | $-18,560,884 |
| Diluted Average Shares | $21,524,884 | $8,991,766 | $8,659,718 | $7,574,953 |
| Basic Average Shares | $21,524,884 | $8,991,766 | $8,659,718 | $7,574,953 |
| Diluted NI Availto Com Stockholders | $-11,942,000 | $-14,928,960 | $-19,533,683 | $-30,219,454 |
| Otherunder Preferred Stock Dividend | $3,054,680 | $0 | - | - |
| Preferred Stock Dividends | $466,141 | $834,677 | $875,540 | $1,088,977 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $-553,856 | $9,777 | $-483,873 | $-683,559 |
| Research And Development | $2,155,660 | $2,571,826 | $3,229,879 | $2,744,587 |
| Selling General And Administration | $10,857,797 | $14,612,724 | $17,621,865 | $18,562,369 |
| Other Gand A | $10,857,797 | $14,612,724 | $17,621,865 | $18,562,369 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-30,014,100 | $-29,976,817 | $-19,845,385 | $-2,144,736 |
| Total Assets | $5,640,954 | $5,942,625 | $6,510,544 | $16,677,970 |
| Total Non Current Assets | $1,001,662 | $1,472,052 | $1,790,341 | $1,355,159 |
| Non Current Prepaid Assets | $109,297 | $85,000 | $85,000 | $85,000 |
| Non Current Accounts Receivable | $70,713 | $149,907 | $96,344 | - |
| Current Assets | $4,639,292 | $4,470,573 | $4,720,202 | $15,322,811 |
| Inventory | $1,555,385 | $1,879,402 | $2,337,006 | $842,924 |
| Receivables | $2,718,762 | $1,805,111 | $1,812,736 | $2,412,958 |
| Other Receivables | $1,059,990 | $336,456 | $588,599 | $406,280 |
| Accounts Receivable | $1,658,772 | $1,468,655 | $1,224,137 | $2,006,678 |
| Cash Cash Equivalents And Short Term Investments | $365,145 | $786,060 | $570,460 | $12,066,929 |
| Cash And Cash Equivalents | $365,145 | $786,060 | $570,460 | $12,066,929 |
| Cash Financial | $365,145 | $786,060 | $570,460 | $12,066,929 |
| Prepaid Assets | - | - | - | $406,280 |
| Debt | ||||
| Net Debt | $24,795,952 | $21,706,244 | $17,253,617 | $1,956,543 |
| Total Debt | $26,090,213 | $23,878,790 | $19,546,172 | $15,353,810 |
| Long Term Debt And Capital Lease Obligation | $13,540,189 | $11,784,948 | $14,436,096 | $13,603,490 |
| Long Term Debt | $13,142,359 | $10,855,833 | $13,049,609 | $12,483,472 |
| Current Debt And Capital Lease Obligation | $12,550,024 | $12,093,842 | $5,110,076 | $1,750,320 |
| Current Debt | $12,018,738 | $11,636,471 | $4,774,468 | $1,540,000 |
| Other Current Borrowings | $12,018,738 | $11,636,471 | $4,774,468 | $1,540,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $35,655,054 | $35,919,442 | $26,355,929 | $18,822,706 |
| Total Non Current Liabilities Net Minority Interest | $15,018,906 | $13,220,616 | $15,195,161 | $13,955,892 |
| Derivative Product Liabilities | $1,478,717 | $1,435,668 | $759,065 | $352,402 |
| Current Liabilities | $20,636,148 | $22,698,826 | $11,160,768 | $4,866,814 |
| Other Current Liabilities | $424,200 | $991,866 | $1,008,216 | $520,747 |
| Current Deferred Liabilities | $25,322 | $21,550 | $0 | - |
| Payables And Accrued Expenses | $7,636,602 | $9,591,568 | $5,042,476 | $2,595,747 |
| Payables | $4,602,309 | $5,221,992 | $3,435,123 | $1,159,477 |
| Accounts Payable | $4,602,309 | $5,221,992 | $3,435,123 | $1,159,477 |
| Equity | ||||
| Common Stock Equity | $-32,014,391 | $-31,465,744 | $-19,845,392 | $-2,144,744 |
| Preferred Stock Equity | $2,000,291 | $1,488,927 | $7 | $8 |
| Total Equity Gross Minority Interest | $-30,014,100 | $-29,976,817 | $-19,845,385 | $-2,144,736 |
| Stockholders Equity | $-30,014,100 | $-29,976,817 | $-19,845,385 | $-2,144,736 |
| Other Equity Interest | $284,244 | $269,065 | $24,999 | $102,299 |
| Gains Losses Not Affecting Retained Earnings | $145,792 | $32,378 | $-152,797 | $-768,656 |
| Other Equity Adjustments | $145,792 | $32,378 | $-152,797 | $-768,656 |
| Retained Earnings | $-139,441,785 | $-127,499,785 | $-112,570,825 | $-93,037,142 |
| Other | ||||
| Ordinary Shares Number | $26,241,967 | $9,514,440 | $8,752,430 | $8,546,173 |
| Share Issued | $26,241,967 | $9,514,440 | $8,752,430 | $8,546,173 |
| Tangible Book Value | $-32,014,391 | $-31,465,744 | $-19,845,392 | $-2,144,744 |
| Invested Capital | $-6,853,294 | $-8,973,440 | $-2,021,315 | $11,878,728 |
| Working Capital | $-15,996,856 | $-18,228,253 | $-6,440,566 | $10,455,997 |
| Capital Lease Obligations | $929,116 | $1,386,486 | $1,722,095 | $1,330,338 |
| Total Capitalization | $-16,871,741 | $-19,120,984 | $-6,795,776 | $10,338,736 |
| Additional Paid In Capital | $106,971,115 | $95,723,083 | $92,844,478 | $91,507,478 |
| Capital Stock | $2,026,534 | $1,498,442 | $8,760 | $51,285 |
| Common Stock | $26,243 | $9,515 | $8,753 | $51,277 |
| Preferred Stock | $2,000,291 | $1,488,927 | $7 | $8 |
| Long Term Capital Lease Obligation | $397,830 | $929,115 | $1,386,487 | $1,120,018 |
| Current Deferred Revenue | $25,322 | $21,550 | $0 | - |
| Current Capital Lease Obligation | $531,286 | $457,371 | $335,608 | $210,320 |
| Current Accrued Expenses | $3,034,293 | $4,369,576 | $1,607,353 | $1,436,270 |
| Net PPE | $821,652 | $1,237,145 | $1,608,997 | $1,270,159 |
| Accumulated Depreciation | $-20,168 | $-14,215 | $-8,262 | $-2,308 |
| Gross PPE | $841,820 | $1,251,360 | $1,617,259 | $1,272,467 |
| Leases | $12,928 | $12,928 | $12,928 | $12,928 |
| Other Properties | $812,053 | $1,221,593 | $1,587,492 | $1,242,700 |
| Machinery Furniture Equipment | $16,839 | $16,839 | $16,839 | $16,839 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $329,720 | $750,702 | $1,150,271 | $374,470 |
| Raw Materials | $1,225,665 | $1,128,700 | $1,186,735 | $468,454 |
| Buildings And Improvements | - | - | - | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,380,177 | $-6,693,912 | $-13,547,935 | $-15,193,151 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,380,177 | $-6,693,912 | $-13,547,935 | $-15,163,384 |
| Cash Flow From Continuing Operating Activities | $-2,380,177 | $-6,693,912 | $-13,547,935 | $-15,163,384 |
| Operating Gains Losses | $553,856 | $-9,777 | $483,873 | $683,559 |
| Investing Activities | ||||
| Investing Cash Flow | - | - | $0 | $-29,767 |
| Cash Flow From Continuing Investing Activities | - | - | $0 | $-29,767 |
| Capital Expenditure | - | - | - | $-29,767 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $1,857,759 | $2,944,285 | $0 | $14,895,805 |
| Financing Cash Flow | $1,929,259 | $6,741,685 | $2,001,603 | $25,168,230 |
| Cash Flow From Continuing Financing Activities | $1,929,259 | $6,741,685 | $2,001,603 | $25,168,230 |
| Cash Dividends Paid | $-29,984 | $-18,016 | $-946,780 | $-966,110 |
| Preferred Stock Dividend Paid | $-29,984 | $-18,016 | $-946,780 | $-966,110 |
| Net Preferred Stock Issuance | $1,732,532 | $2,825,000 | $-895,556 | $-130,000 |
| Preferred Stock Issuance | $1,732,532 | $2,825,000 | $0 | $100,000 |
| Net Common Stock Issuance | $125,227 | $119,285 | $0 | $14,795,805 |
| Common Stock Issuance | $125,227 | $119,285 | $0 | $14,795,805 |
| Repurchase Of Capital Stock | - | $0 | $-895,556 | $-230,000 |
| Other | ||||
| Issuance Of Debt | $1,835,000 | $2,962,386 | $2,355,318 | $12,256,463 |
| Interest Paid Supplemental Data | $3,611,939 | $2,022,221 | $1,620,012 | $553,265 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $365,145 | $786,060 | $570,460 | $12,066,929 |
| Beginning Cash Position | $786,060 | $570,460 | $12,066,929 | $2,201,562 |
| Effect Of Exchange Rate Changes | $30,003 | $167,827 | $49,863 | $-109,712 |
| Changes In Cash | $-450,918 | $47,773 | $-11,546,332 | $9,975,079 |
| Net Issuance Payments Of Debt | $101,484 | $3,815,416 | $3,831,439 | $10,596,243 |
| Net Short Term Debt Issuance | $-1,733,516 | $853,030 | $1,476,121 | $-1,660,220 |
| Net Long Term Debt Issuance | $1,835,000 | $2,962,386 | $2,355,318 | $12,256,463 |
| Long Term Debt Issuance | $1,835,000 | $2,962,386 | $2,355,318 | $12,256,463 |
| Change In Working Capital | $962,229 | $3,682,697 | $2,308,764 | $-117,583 |
| Change In Payables And Accrued Expense | $1,496,966 | $3,271,198 | $3,341,468 | $948,997 |
| Change In Prepaid Assets | $-747,831 | $252,143 | $-224,819 | $-60,665 |
| Change In Inventory | $324,017 | $457,604 | $-1,494,082 | $-570,431 |
| Change In Receivables | $-110,923 | $-298,248 | $686,197 | $-435,484 |
| Changes In Account Receivables | $-110,923 | $-298,248 | $686,197 | $-435,484 |
| Other Non Cash Items | $3,057,266 | $2,695,568 | $1,663,987 | $12,485,196 |
| Stock Based Compensation | $1,461,698 | $1,025,930 | $647,631 | $913,613 |
| Depreciation Amortization Depletion | $5,953 | $5,953 | $5,953 | $2,308 |
| Depreciation And Amortization | $5,953 | $5,953 | $5,953 | $2,308 |
| Depreciation | $5,953 | $5,953 | $5,953 | $2,308 |
| Gain Loss On Investment Securities | $553,856 | $-9,777 | $483,873 | $683,559 |
| Net Income From Continuing Operations | $-8,421,179 | $-14,094,283 | $-18,658,143 | $-29,130,477 |
| Proceeds From Stock Option Exercised | - | $0 | $12,500 | $872,292 |
| Preferred Stock Payments | - | $0 | $-895,556 | $-230,000 |
| Short Term Debt Issuance | - | - | $3,831,439 | $0 |
| Net PPE Purchase And Sale | - | - | $0 | $-29,767 |
| Purchase Of PPE | - | - | $0 | $-29,767 |
| Repayment Of Debt | - | - | - | $-1,660,220 |
| Short Term Debt Payments | - | - | - | $-1,660,220 |
| Provisionand Write Offof Assets | - | - | - | - |
Fetched: 2026-02-02